Nia Impact Advisors LLC Purchases 3,839 Shares of Hologic, Inc. (NASDAQ:HOLX)

Nia Impact Advisors LLC increased its position in Hologic, Inc. (NASDAQ:HOLX) by 7.2% during the 4th quarter, Holdings Channel reports. The firm owned 57,077 shares of the medical equipment provider’s stock after acquiring an additional 3,839 shares during the quarter. Hologic comprises approximately 1.3% of Nia Impact Advisors LLC’s investment portfolio, making the stock its 24th largest holding. Nia Impact Advisors LLC’s holdings in Hologic were worth $4,115,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new stake in Hologic during the 4th quarter valued at $133,414,000. Boston Partners boosted its position in Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Champlain Investment Partners LLC bought a new stake in Hologic during the 4th quarter valued at $79,291,000. Northern Trust Corp boosted its position in Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock valued at $226,898,000 after acquiring an additional 668,086 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock valued at $293,434,000 after acquiring an additional 572,187 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus acquired 5,445 shares of the business’s stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now owns 5,445 shares of the company’s stock, valued at $300,781.80. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Stock Down 2.9%

Shares of NASDAQ HOLX opened at $57.12 on Wednesday. The firm has a market cap of $12.73 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 2.14 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The business’s 50 day moving average is $59.26 and its two-hundred day moving average is $67.94.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.03 earnings per share. Research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent analyst reports. Evercore ISI lowered their price objective on Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a research report on Friday, May 2nd. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Finally, William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.